Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Indeed it is, especially at these prices
I plan to buy some more in the next day or two
So ...….UCB Pharma has struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The takeover will give UCB control of a phase 3 rival to Alexion’s Soliris that some analysts have tipped to rack up blockbuster sales.
So what are these block buster sale figures?
It's just over a billion dollars. Similar to MED...
I just hope the phase 3 trials exceed our expectations. If the data is excellent, we all could be in for a good surprise.
At last, an updated and much improved website.
bought at £4.80 today.
Will add more if it remains at this level next week.
Can’t argue with the div yield at a purchase price below £5!
Yep, trial will probably end by Mid October as there is a 4 week run in period too, where the baseline EF score is established.
Not long to go now.
Good luck all.
Giving a prediction with no timeline is totally worthless.
Anyway I see it has not dipped to the level you said (in March!!!) which is not to say it can’t do so in future however anyone who invested at that point would still have made some income from dividends.
Anyway I’m not in the business of making predictions. Good luck all. The company seems to have seen the worst of it IMHO.
If you actually read that paper on the phase 2 trials you can actually understand why the big pharma’s didn’t go for a deal.
It actually comes down to the fact that we need to show an increase in efficacy.
With the higher doses we should be able to achieve this. Not only that, but with the higher doses the residual amount of GTN should also help with the duration aspect too.
In the phase 2, 46 percent of respondents did not show an improvement on either placebo or Med.
14 percent of the placebo group showed an improvement.
Now when you compare that to the fact that this time round, 25 percent of the trial will be taking placebo and the fact that 80 percent of participants chose to carry on, it speaks volumes. Most likely pointing to the fact that we will indeed see an increase in efficacy. (Especially as there is no incentive , such as getting paid)
Even if we assume a worst case 50 percent placebo response rate, that would equate to 12.5 percent of the participants , however we have 80 percent selecting to carry on… I think it deserves pause for thought
Why the hell would I decide to carry on using a gel if I were not seeing some benefit?
I’m excited and look forward to the headline data.
Hahaha
Good one Thomas
Counteracting zwartkops like you said you would
Very amusing
Thomas - I can't access you-tube from where I am
Can you confirm again if I understood you right.
In the proactive interview, JB confirms the participants are not being paid for the open label part?
Thomas
That was the FIRST thing I thought of when I heard of the 80 percent that were following on with the treatment..
If they are NOT being paid, then this in my mind changes the picture considerably
Cast your minds back.
It was Thornton and Ross ( STADA ) that was dragging their feet with filing of the regulatory dossier and it was only really filed (if my memory serves me correct) in July after all discussions had been finished and FUM had made the decision to go it alone.
Now we see the similarities again when it comes to responding to the MHRA… and it coincides with yet again another milestone.
I don’t think it’s a coincidence
It all hangs on good phase 3 data. The increased doses should (I believe) have the desired effect and show increased efficacy
Excellent news
Another potential pathway for our tech
Intellectual property to be jointly owned
All costs covered
What’s not to like!!
When was this chat? any links?
So whenever he says it’s going down, it actually goes up.
This excellent for us shareholders!
The IC article assumes a pessimistic case of 230 million pounds per annum by 2028 and 500 million dollars in the most optimistic case. I think it is important to point out that this forecast was based on "prescription" only scenario.
The figures do not account for the over the counter scenario which was estimated as 650 million dollars (or thereabouts) on top of the prescription sales.If we assume the 230 million dollars as the pessimistic case and half of 650 million dollars as the pessimistic case for OTC, we still arrive at a figure in excess of 500 million dollars from which a royalty would be paid to FUM if thats the route the company chooses.
I personally believe the asset and with it the company should be sold as we have not had much luck when it comes to licensing deals and companies honouring their licensing commitments. The lowest risk to all investors would be to sell the asset/company once we get the phase 3 results which should hopefully show that MED2005 is a first line therapy for ED for a significant proportion of men.
hawkhead has a point.
I have to admit, hawkhead's comment "Will break 50p today. But if it doesn't it might go down even. Don't rule out staying the same either" did make me laugh out loud.
Some people believe in charts, some don't. Each to their own
Good Morning
What a pleasant atmosphere we have this morning
hahahaah It's spiderman again...
Thomas - he's asking for advice from you and it seems like it's another bitter and twisted individual.
I think the advice you should give him is, "if phase 3 are positive the share price will be 4567892843654.00 and if it's negative it'll be 0.0000000000001.
That should give Spiderman enough of a range to work with.
kdonkey - The Erectile Function score is a series of questions and I think the maximum score you can get is 30. For example, one of the questions is "are you always able to maintain an erection throughout intercourse"... then the answers are "yes always".. that may give you 5 points. The next answer may be "yes mostly".. that would give 4 points etc etc... one answer may be "never".. that would give 0 points...
According to the internation guidelines for Erectile function scoring, if someone got a total score between 17 and 25 out of a maximum possible score of 30, they would be categorised as having mild Erectile Dysfunction.
Hope this clarifies!
Hi Tommy
Before phase 2 was carried out, the only side effect profiles that were available were the one's that were done in a clinical setting. As you know, the side effect profiles observed in a clinical setting is far higher than in "home use". In fact the low side effect profile that was recorded in phase 2 "home use" actually surprised everyone.
Given that they only had the clinical side effect profiles to go with, they chose only the 0.2% dose. Futura Medical were advised against using a higher dose due to the side effect profile seen in a clinical setting.
Hindsight is a wonderful thing as they say!
The other reason was to save on costs for the trial